A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112393 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Shengsheng Mei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National …. Hauptthemen laut MEDLINE: B7-H1 Antigen, Oncolytic Virotherapy, Oncolytic Viruses, Adenoviridae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Recombinant adenovirus serotype 5 (Ad5)-mediated virotherapy is a maturing technique in cancer treatment. However, the utility of adenovirus (Ad) has been limited by low expression of coxsackievirus and adenovirus receptor (CAR) in cancer cells resulting in poor infectivity of Ads. To overcome the problem, we aimed to develop a novel tropism-modified oncolytic adenovirus, ZD55-F-HI-sPD-1-EGFP, which contains the epitope of PD-1 (70-77aa) at the HI-loop of Ad fiber. Trimerization of Fiber-sPD-1 was confirmed by immunoblot analysis. ZD55-F-HI-sPD-1-EGFP shows a remarkable improvement in viral infection rate and gene transduction efficiency in the PD-L1-positive cancer cells. Competition assays with a PD-L1 protein reveals that cell internalization of ZD55-F-HI-sPD-1-EGFP is mediated by both CAR and PD-L1 at a high dose. The progeny virus production capacity showed that sPD-1 incorporated fiber-modified oncolytic Ad replication was not affected. Furthermore, treating with ZD55-F-HI-sPD-1-EGFP significantly increased viral infection rate and enhanced anti-tumor effect in vivo. This study demonstrates that the strategy to expand tropism of oncolytic Ad may significantly improve therapeutic profile for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Cancer Institute of the Second Affiliated Hospital (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), School of Medicine, Zhejiang University, Hangz…
Förderung
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Mei, S., Peng, S., Vong, E. G., & Zhan, J. (2024). A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112393
Vancouver
Mei S, Peng S, Vong EG, Zhan J. A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112393
BibTeX
@article{Mei2024,
author = {Mei, Shengsheng and Peng, Shanshan and Vong, Eu Gene and Zhan, Jinbiao},
title = {A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112393}
}
EUVIMED